Covid Bivalent Vaccines: What To Know About The New Boosters
As an alternative, it would allow the Centers for Medicare and Medicaid Solutions to negotiate the charges of ten high-priced legacy drugs in 2023, for agreements that would take effect in 2025. Drugmakers that do not participate in the negotiations would face a special excise tax, and the provision contains various exemptions for newly released drugs and particular biologics that have been out there for much less than 12 years. Chief executive Albert Bourla said Manchin and Schumer have been “wrong” to “single out” the pharmaceutical market in in search of cost savings for the government. His loved ones rather...